Former FDA commissioner sentenced in stock case

Share this article:
A judge sentenced former FDA commissioner Lester Crawford to three years supervised probation and fines of roughly $90,000 for lying about stocks he owned in agency-regulated companies, the Associated Press reported. Magistrate Judge Deborah Robinson’s sentence spares Crawford jail time but is stiffer than the punishment of $50,000 proposed by federal prosecutors and his defense attorney. The judge also ordered Crawford to conduct 50 hours of community service and to pay the costs of his supervised probation. Last October, Crawford pleaded guilty to charges of having a conflict of interest and false reporting of information about stocks he and his wife owned in food, beverage and medical device companies he regulated while head of the FDA. The two charges are misdemeanors and each carries a maximum penalty of one year in prison and a $100,000 fine. Crawford and his wife made roughly $39,000 from exercising options and dividends from the illegally held stocks in companies such as Embrex and PepsiCo, according to published reports. “I want to assure you that I accept responsibility for what I’ve done” Crawford told the judge during the hearing. “I should have communicated better with the people helping me.” Crawford declined to comment after the sentence, the AP reported. Crawford, a veterinarian and food-safety expert, resigned from the FDA in September 2005 without explanation after holding the job of commissioner for only two months.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...